Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
First Claim
Patent Images
1. A method of adjunctive treatment of an immune dysfunction characterized by adverse T-cell activation or proliferation in a subject, comprising:
- administering to a subject in need of treatment for adverse T-cell activation or proliferation associated with an immune dysfunction, by an effective route and in an effective amount to treat the adverse T-cell activation or proliferation cells that;
are not embryonic stem cells, embryonic germ cells, or germ cells, express telomerase, have undergone at least 10-40 cell doublings in culture, have a normal karyotype, are allogeneic to the subject, do not provoke a deleterious immune response in the subject, and are effective to treat the adverse T-cell activation or proliferation in the subject, wherein the cells are administered adjunctively to one or more other treatments administered to the subject, and wherein the cells have not been genetically engineered to improve their immunological properties, wherein the immune dysfunction is not GVHD and is not diabetes.
4 Assignments
0 Petitions
Accused Products
Abstract
Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
45 Citations
39 Claims
-
1. A method of adjunctive treatment of an immune dysfunction characterized by adverse T-cell activation or proliferation in a subject, comprising:
- administering to a subject in need of treatment for adverse T-cell activation or proliferation associated with an immune dysfunction, by an effective route and in an effective amount to treat the adverse T-cell activation or proliferation cells that;
are not embryonic stem cells, embryonic germ cells, or germ cells, express telomerase, have undergone at least 10-40 cell doublings in culture, have a normal karyotype, are allogeneic to the subject, do not provoke a deleterious immune response in the subject, and are effective to treat the adverse T-cell activation or proliferation in the subject, wherein the cells are administered adjunctively to one or more other treatments administered to the subject, and wherein the cells have not been genetically engineered to improve their immunological properties, wherein the immune dysfunction is not GVHD and is not diabetes. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
- administering to a subject in need of treatment for adverse T-cell activation or proliferation associated with an immune dysfunction, by an effective route and in an effective amount to treat the adverse T-cell activation or proliferation cells that;
-
21. A method of suppressing adverse T-cell proliferation in a subject, comprising:
- suppressing adverse T-cell proliferation in a subject by administering to a subject by an effective route and in an effective amount to suppress adverse T-cell proliferation expanded, multipotent non-embryonic, non-germ cells that;
can differentiate into cells of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages;
express telomerase;
have undergone at least 10-40 cell doublings in culture prior to administration;
are allogeneic or xenogeneic to the subject;
do not provoke a deleterious immune response in the subject; and
are effective to suppress adverse T-cell proliferation, wherein the cells are administered adjunctively to one or more other treatments, and wherein the cells have not been genetically engineered to improve their immunological properties, wherein cells are not administered to suppress adverse T-cell proliferation of GVHD or diabetes. - View Dependent Claims (22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)
- suppressing adverse T-cell proliferation in a subject by administering to a subject by an effective route and in an effective amount to suppress adverse T-cell proliferation expanded, multipotent non-embryonic, non-germ cells that;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeOregon Health & Science University
-
Original AssigneeAthersys, Inc., Oregon Health & Science University
-
InventorsDeans, Robert, Van't Hof, Wouter, Maziarz, Richard, Kovacsovics, Magdalena, Streeter, Philip
-
Primary Examiner(s)Kim, Taeyoon
-
Application NumberUS12/093,159Publication NumberTime in Patent Office4,198 DaysField of SearchUS Class CurrentCPC Class CodesA61K 2035/122 for inducing tolerance or s...A61K 2035/124 the cells being hematopoiet...A61K 35/12 Materials from mammals; Com...A61K 35/14 Blood; Artificial blood per...A61K 35/28 Bone marrow; Haematopoietic...A61K 39/001 Preparations to induce tole...A61K 45/06 Mixtures of active ingredie...A61N 5/10 X-ray therapy; Gamma-ray th...A61P 19/00 Drugs for skeletal disordersA61P 35/00 Antineoplastic agentsA61P 35/02 specific for leukemiaA61P 37/00 Drugs for immunological or ...A61P 37/02 ImmunomodulatorsA61P 37/04 ImmunostimulantsA61P 37/06 Immunosuppressants, e.g. dr...A61P 43/00 Drugs for specific purposes...A61P 7/00 Drugs for disorders of the ...A61P 7/06 AntianaemicsC12N 5/0607 Non-embryonic pluripotent s...
